Patient‐reported outcomes in advanced NSCLC before and during the COVID‐19 pandemic: Real‐world data from the German prospective CRISP Registry (AIO‐TRK‐0315)

• Published in: International journal of cancer Vol. 154; no. 11; pp. 1967 - 1978
• Main Authors: Sebastian, Martin, Eberhardt, Wilfried E. E., Heyde, Eyck, Dörfel, Steffen, Wiegand, Jörg, Schiefer, Clemens, Losem, Christoph, Jänicke, Martina, Fleitz, Annette, Zacharias, Stefan, Kaiser‐Osterhues, Anja, Hipper, Annette, Dietel, Corinna, Bleckmann, Annalen, Benkelmann, Robin, Boesche, Michael, Grah, Christian, Müller, Annette, Griesinger, Frank, Thomas, Michael
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01-06-2024; Wiley Subscription Services, Inc
• Subjects: Anxiety; Clinical outcomes; cohort studies; Comorbidity; COVID-19; Lung cancer; Mental depression; Metastases; Non-small cell lung carcinoma; non‐small cell lung cancer; Pandemics; Patients; patient‐reported outcomes; Quality of life; real world; Small cell lung carcinoma; cohort studies; real world; COVID‐19; non‐small cell lung cancer; patient‐reported outcomes
• ISSN: 0020-7136; 1097-0215
• DOI: 10.1002/ijc.34868

Patients with lung cancer under treatment have been associated with a high risk of COVID‐19 infection and potentially worse outcome, but real‐world data on patient‐reported outcomes (PROs) are rare. We assess patients' characteristics and PROs before and during the COVID‐19 pandemic in an advanced non‐small cell lung cancer (NSCLC) cohort in Germany. Patients with locally advanced or metastatic NSCLC from the prospective, multicentre, observational CRISP Registry (NCT02622581) were categorised as pre‐pandemic (March 2019 to Feb 2020, n = 1621) and pandemic (March 2020 to Feb 2021, n = 1317). From baseline to month 15, patients' health‐related quality of life (HRQoL) was assessed by FACT‐L, anxiety and depression by PHQ‐4. Association of pandemic status with time to deterioration (TTD) in QoL scales adjusted for potential covariates was estimated using Cox modelling. PROs were documented for 1166 patients (72%) in the pre‐pandemic, 979 (74%) in the pandemic group. Almost 60% of patients were male, median age was 66 years, comorbidities occurred in 85%. Regarding HRQoL, mean‐change‐from‐baseline plots hardly differed between both samples. Approximately 15%–21% of patients reported anxiety, about 19%–27% signs of depression. For the pandemic group, TTD was slightly, but statistically significantly, worse for the physical well‐being‐FACT‐G subscale (HR 1.15 [95%CI 1.02–1.30]) and the anxiety‐GAD‐2 subscale (HR 1.14 [95%CI 1.01–1.29]). These prospectively collected real‐world data provide valuable insights into PROs before and during the COVID‐19 pandemic in advanced NSCLC. For the patients, the pandemic seemed to be less of a burden than the disease itself, as there was a considerable proportion of patients with anxiety and depression in both groups.
What's new?
The COVID‐19 pandemic has had far‐reaching impacts on public health and disease management, and patients with lung cancer are at higher risk of COVID‐19 infection. Here, the authors examined how COVID‐19 affected patient‐reported outcomes for people with advanced non‐small cell lung cancer (NSCLC). Using data from the CRISP Registry in Germany, the authors assessed patients' quality of life, including anxiety and depression, before and during the pandemic. Although they found considerable anxiety and depression both before and after the onset of the pandemic, the pandemic itself did not seem to pose a particular burden.